H.C. Wainwright analyst Oren Livnat raised the firm’s price target on Xeris Biopharma (XERS) to $8 from $6.60 and keeps a Buy rating on the shares. The company’s first-time 2025 guidance for $255M-$275M in revenue is a “surprising” 11% above estimates and up 30% year-over-year at the midpoint, the analyst tells investors in a research note. The firm continues to view Xeris Biopharma as a top pick for 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS: